Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

Key facts

Sponsor

University of Minnesota

Principal Investigator

Holly Boyer, MD

University of Minnesota

Intervention

Sclerotherapy(drug)

Enrollment

18 target

Eligibility

18 years · All sexes

Timeline

2011 – 2014

Study locations (1)

• University of Minnesota Otolaryngology Clinic, Minneapolis, Minnesota, United States

Collaborators

American Rhinologic Society

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hereditary hemorrhagic telangiectasia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07255846
  A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
  Terremoto Biosciences Inc.
• ENROLLING BY INVITATIONNCT07445347
  Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network
  Poitiers University Hospital
• RECRUITINGPHASE1, PHASE2NCT06659640
  A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
  Alnylam Pharmaceuticals
• ACTIVE NOT RECRUITINGNCT07018401
  Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
  Massachusetts General Hospital
• ENROLLING BY INVITATIONNCT06261333
  Quality of Life in Patients With Hemorrhagic Telangiectasia
  University Hospital, Essen
• ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT03850964
  Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
  Cure HHT
• RECRUITINGNANCT05641142
  Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia
  University Hospital, Clermont-Ferrand
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05406362
  Assess Safety and Efficacy of VAD044 in HHT Patients
  Vaderis Therapeutics AG

See all trials for Hereditary hemorrhagic telangiectasia →